Nerviano Medical Sciences

Focus: Nerviano Medical Sciences is an Italian oncology-focused biotech company developing novel small molecule and targeted therapies for hematologic and solid tumors. The company operates as a research-driven organization with a diversified pipeline across multiple cancer indications.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Nerviano Medical Sciences

AI assessmentNot Hiring

No open roles listed right now. Follow Nerviano Medical Sciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PHA-848125AC

Solid Tumour

Phase 1

Clinical Trials (1)

NCT01300468Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1

Help build intelligence for Nerviano Medical Sciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a highly diversified oncology pipeline with 18 active trials spanning hematology, solid tumors, and rare cancers—exposure to multiple therapeutic modalities and disease areas
Participation in early-stage drug development (83% of pipeline in Phase 1) offers learning opportunities in translational research, mechanism validation, and clinical trial design
Italian biotech with European research heritage provides geographic flexibility and potential access to European regulatory pathways and partnerships

Watch Out For

Currently zero open job listings signals limited near-term hiring and potential talent constraints for growth initiatives
Heavy emphasis on early-stage programs (15 Phase 1, 6 Phase 2, only 1 Phase 3) means minimal near-term revenue generation and extended runway to commercial milestone validation

Generated by Claude from Nerviano Medical Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NMS-03305293

Ovarian Cancer

Phase 1

Clinical Trials (1)

NCT06930755Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Phase 1

NMS-1116354

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT01016327Study of NMS-1116354 in Solid Tumors

Phase 1

NMS-1116354

Advanced/Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT01092052Study of NMS-1116354 in Advanced/Metastatic Solid Tumors

Phase 1

NMS-1286937

Advanced or Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT01014429Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1

NMS-03305293

Advanced/Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT04182516Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Phase 1

PHA-793887

Advanced/Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT00996255Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors

Phase 1

NMS-03305293

Small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT06931626Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Phase 1

NMS-03597812

Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT05027594Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Filgrastim test

Healthy Male Subjects

Phase 1

Clinical Trials (1)

NCT01933971Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the Test Injectable Formulation BK0023 vs. Neupogen®

Phase 1

NMS-03597812

Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT06549790Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

NMS-03305293

Glioblastoma

Phase 1/2

Clinical Trials (1)

NCT04910022Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

Phase 1/2

NMS-01940153E

Unresectable Hepatocellular Carcinoma (HCC)

Phase 1/2

Clinical Trials (1)

NCT05630937Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

Phase 1/2

atamparib escalation levels

NSCLC Adenocarcinoma

Phase 1/2

Clinical Trials (1)

NCT07374419Atamparib in Patients With Advanced Solid Tumors

Phase 1/2

NMS-03592088

Acute Myeloid Leukemia (AML)

Phase 1/2

Clinical Trials (1)

NCT03922100Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Phase 1/2

PHA-739358

Multiple Myeloma

Phase 2

Clinical Trials (1)

NCT00872300PHA-739358 for the Treatment of Multiple Myeloma

Phase 2

PHA-739358

Metastatic Hormone Refractory Prostate Cancer

Phase 2

Clinical Trials (1)

NCT00766324PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Phase 2

Cytoreductive Surgery and HIPEC

Ovarian Neoplasms

Phase 3

Clinical Trials (1)

NCT01628380Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer

Phase 3

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 18 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

17 pipeline

Marketed

Pipeline